SenzaGen's 2023 year-end report will be published on February 14, 2024, at 08:30 CET and will be followed by a livestream presentation at 10:00 on the same day. The presentation will be given by SenzaGen’s President and CEO Peter Nählstedt, followed by a Q&A session.

The presentation will be held in Swedish.

Time: Wednesday February 14, 10:00–11:00 CET.
Link to the livestream: https://ir.financialhearings.com/senzagen-year-end-report-2023

The presentation can be watched afterwards at SenzaGen’s website: https://senzagen.com/investors/presentations/

Contacts

Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Mobile: +46 700 23 44 31

Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Mobile: +46 708 20 29 44

About us

SenzaGen is a corporate group that aims to be a leader in in vitro science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® and VitroScreen ORA® test platforms, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company’s Certified Adviser. 

Attachments

Invitation to the presentation of SenzaGen’s year-end report 2023 on Feb 14 at 10.00 CET

© Modular Finance, source Nordic Press Releases